Patent ID: 7201900

Claim:
A method for treating prostate cancer, comprising administering to a prostate cancer patient an effective amount of a monoclonal antibody having an antigen-binding region specific for the extracellular domain of prostate specific membrane antigen, wherein the antigen-binding region of the antibody competitively inhibits the immunospecific binding of a second monoclonal antibody to its target epitope, said second antibody is produced by a hybridoma selected from the group consisting of 3F5.4G6 having ATCC accession number HB12060, 3D71.1 having ATCC accession number HB12309, 4E010-1.14 having ATCC accession number HB12310, 3E11 having ATCC accession number HB12488, 4D8 having ATCC accession number HB12487, 3E6 having ATCC accession number HB12486, 3C9 having ATCC accession number HB12484, 2C7 having ATCC accession number HB12490, 1G3 having ATCC accession number HB12489, 3C4 having ATCC accession number HB12494, 4C8B9 having ATCC accession number HB12492 and 3G6 having ATCC accession number HB12485.